Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Peer support could boost HIV med adherence and curb substance use

NCT ID NCT05933226

Disease control Sponsor: University of Maryland, College Park Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a program called Khanya, where trained peers (people with lived substance use experience) help HIV patients stick to their medication and reduce drug or alcohol use. The program is offered in steps: a basic version first, then a more intensive one if needed. Researchers will compare it to usual care over 12 months in South African primary care clinics. About 160 adults with HIV who have trouble taking their medication and have moderate-to-high substance use risk are taking part.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Khanya (peer-delivered behavioral intervention)
What this could lead to
If it works, this could provide a low-cost, scalable way to improve HIV medication adherence and reduce substance use in primary care settings.
What could go wrong
This is a relatively small trial (160 participants) testing a behavioral intervention, so results may not apply broadly. The intervention relies on peer counselors, which may vary in effectiveness.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 160 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2023

Expected to finish

Feb 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * HIV positive and on ART * ≥18 years of age * At least moderate substance use risk in the past 3 months for at least one non-tobacco substance (measured by the WHO- ASSIST: score ≥11 for alcohol, ≥4 for non-tobacco drugs) * ART nonadherence and/or risk of virologic failure, defined as at least one of the following in the past 12 months 1) re-engaging in care after ≥1 month of being out of care (confirmed by pharmacy refill data) 2) ≥1 episodes of VL \>400 copies/mL 3) on second- or third-line ARTs. Exclusion Criteria: * Severe risk/likely dependence for opiates (WHO ASSIST score \>26) because opiate substitution therapy is largely not available * Severe alcohol dependence symptoms that may warrant medical management of potential withdrawal symptoms/stabilization prior to study participation * Inability to provide informed consent or complete study procedures in isiXhosa or English * In third trimester of pregnancy during baseline * Currently enrolled in another study or treatment program focused on substance use (including Matrix) or ART adherence. * Untreated or undertreated major mental illness that would interfere with study procedures

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Alcohol-related disorders are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

AIDS Alcohol Drinking alcohol-related disorders Behavioral Symptoms HIV infectious disease immune system disorder inborn error of immunity Psychological Well-Being RNA Virus Infections substance abuse substance-related disorder Treatment Adherence and Compliance

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Alcohol-related disorders Drug use Human immunodeficiency virus Substance use

Contacts and locations

Locations

  • University of Cape Town

    Cape Town, Western Cape, South Africa

More trials for these conditions

Other studies related to the condition(s) this trial covers.